Celldex Therapeutics, Inc.
CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receā¦ read more
Healthcare
Biotechnology
40 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$36.90
Price-3.15%
-$1.20
1Y
Price
Market Cap
$2.455b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-330004.5%
EBITDA Margin-334104.5%
Net Profit Margin-275404.5%
Free Cash Flow Margin-330004.5%
EBITDA Margin-334104.5%
Net Profit Margin-275404.5%
Free Cash Flow MarginRevenue
$112k
-92.5%
1y CAGR-56.4%
3y CAGR+5.7%
5y CAGREarnings
-$300.592m
-16.1%
1y CAGR-30.6%
3y CAGR-29.4%
5y CAGREPS
-$4.36
-11.8%
1y CAGR-18.3%
3y CAGR-19.1%
5y CAGRBook Value
$714.564m
$782.349m
Assets$67.785m
Liabilities$4.904m
DebtDebt to Assets
0.6%
-
Debt to EBITDAFree Cash Flow
-$241.817m
-13.2%
1y CAGR-31.1%
3y CAGR-24.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company